Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

Hypersensitivity Clinical Trial

Official title:

HT201307-Cumulative Irritation Patch Test (21 Day)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04531813
• Other study ID #: 18153
• Status: Completed
• Phase: Phase 3
• Start date: June 10, 2013
• Est. completion date: July 1, 2013

Study information

• Verified date: September 2020
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study researchers want to study the potential skin reaction after repeated application of an antifungal cream containing trolamine. The study plans to enroll about 32 healthy female or male participants with the age 18 - 79 years. Researchers will apply on the skin of the upper back between the shoulder blades of the study participants three different patches to cover a small amount of the antifungal cream or 0.3% solution of sodium lauryl sulfate, which is known to cause skin irritation (so called positive control). A third patch will cover a skin area without any product (so called negative control). Participants will return daily to the study center to have new patches containing the test products applied on the same skin area of the back, excluding weekends, for 21 days of continuous skin contact. At each visit the skin will be investigated by the researchers for redness, dryness and other reactions to learn about the skin reaction after repeated application.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 32
• Est. completion date: July 1, 2013
• Est. primary completion date: July 1, 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 79 Years

Eligibility

Inclusion Criteria:

• Participants must have been aged 18 to 79 years, inclusive.

• Participants must have understood and executed an Informed Consent Form (ICF).

• Participants (if female) must have been willing to take a urine pregnancy test prior to the initiation and at the completion of the trial.

• Participants must have been capable of understanding and following directions.

• Participants must have been considered reliable.

Exclusion Criteria:

• Participants who were in ill health or taking medication, other than birth control, which could have influenced the purpose, integrity or outcome of the trial.

• Participants who had any visible skin disease that might have been confused with a skin reaction to the test material.

• Participants who were participating in another clinical trial at this facility or any other facility.

• Participants who were using topical or systemic steroids or antihistamines for at least 7 days prior to trial initiation and during the duration of the trial.

• Participants who had a history of adverse reaction to adhesive tape, cosmetics, over-the-counter (OTC) drugs or other personal care products.

• Participants judged by the principal investigator (PI) to be inappropriate for the trial.

• Female participants who were pregnant as evidenced by a positive urine pregnancy test, planning to become pregnant, or nursing during the course of the trial.

Related Conditions & MeSH terms

• Hypersensitivity

Intervention

Drug:
• Butenafine HCl 1% (BAY1896425)
Approximately 0.2 g of cream containing butenafine HCl 1% daily (excluding weekends) was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the skin test site. The total dose applied to each participant completing the trial was 3 g.
• Positive Control-Sodium lauryl sulfate (SLS)
Approximately 0.2 mL of 0.3% solution of sodium lauryl sulfate was applied to the absorbent pad portion of a semi-occlusive dressing, which was then applied to the Positive Control test site.

Other:
• Negative Control
A blank patch was applied to the Negative Control test site.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative Irritation Total (CIT) Score	Prior to each patch application and after the last patch removal, the test sites were evaluated for gross changes according to the Erythema Scoring Scale: 0 = No visible erythema; 0.5 = Slight, barely perceptible erythema; 1 = Mild erythema; 2 = Moderate erythema; 3 = Marked erythema; 4 = Severe erythema. The Cumulative Irritation Total is generated by totaling the Erythema Scoring Scale scores of the Investigational Product for each subject completing the trial and then adding those totals. Data is being reported for all the 30 participants as a group.	21 days

External Links

•   Click here to find results for studies related to Bayer Healthcare products.